Myelodysplastic Syndromes.
作者信息
Cazzola Mario
机构信息
From Fondazione IRCCS Policlinico San Matteo and the University of Pavia, Pavia, Italy.
出版信息
N Engl J Med. 2020 Oct 1;383(14):1358-1374. doi: 10.1056/NEJMra1904794.
PMID:32997910
Abstract
摘要
相似文献
1
Myelodysplastic Syndromes.骨髓增生异常综合征
N Engl J Med. 2020 Oct 1;383(14):1358-1374. doi: 10.1056/NEJMra1904794.
2
Novel therapies in low- and high-risk myelodysplastic syndrome.低危和高危骨髓增生异常综合征的新型治疗方法。
Expert Rev Hematol. 2019 Oct;12(10):893-908. doi: 10.1080/17474086.2019.1647778. Epub 2019 Jul 31.
3
Improving Treatment for Myelodysplastic Syndromes Patients.改善骨髓增生异常综合征患者的治疗。
Curr Treat Options Oncol. 2018 Oct 25;19(12):66. doi: 10.1007/s11864-018-0583-4.
4
Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine.骨髓增生异常综合征/急性髓系白血病中TWIST1表达升高会降低地西他滨去甲基化治疗的疗效。
Haematologica. 2020 Oct 1;105(10):e502. doi: 10.3324/haematol.2019.235325.
5
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.阿扎胞苷对急性髓系白血病异基因干细胞移植后复发患者的临床活性。
Haematologica. 2016 Jul;101(7):879-83. doi: 10.3324/haematol.2015.140996. Epub 2016 Apr 14.
6
First-line Therapeutic Strategies for Myelodysplastic Syndromes.骨髓增生异常综合征的一线治疗策略
Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S31-S36. doi: 10.1016/j.clml.2017.02.013.
7
Myelodysplasia: when to treat and how.骨髓发育异常：何时治疗及如何治疗。
Best Pract Res Clin Haematol. 2006;19(2):293-300. doi: 10.1016/j.beha.2005.11.005.
8
Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.表观遗传学在临床实践中的应用：阿扎胞苷和地西他滨在骨髓增生异常综合征和急性髓系白血病中的应用实例。
Leukemia. 2013 Sep;27(9):1803-12. doi: 10.1038/leu.2013.173. Epub 2013 Jun 12.
9
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.骨髓增生异常综合征：2015 年诊断、风险分层和治疗更新。
Am J Hematol. 2015 Sep;90(9):831-41. doi: 10.1002/ajh.24102.
10
[Current treatment options for myelodysplastic syndromes].[骨髓增生异常综合征的当前治疗选择]
Dtsch Med Wochenschr. 2010 Sep;135(38):1863-9. doi: 10.1055/s-0030-1263328. Epub 2010 Sep 14.
引用本文的文献
1
Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practice.在日常临床实践中分子数据可用性有限的情况下，IPSS-M、IPSS-R和AIPSS-MDS预后评估的比较。
Ann Hematol. 2025 Sep 6. doi: 10.1007/s00277-025-06570-0.
2
Advances in the study of TIM3 in myelodysplastic syndrome.骨髓增生异常综合征中TIM3的研究进展
Front Immunol. 2025 Aug 19;16:1647401. doi: 10.3389/fimmu.2025.1647401. eCollection 2025.
3
Analysis of chromatin accessibility associated with azacitidine response in higher-risk myelodysplastic neoplasms.高危骨髓增生异常肿瘤中与阿扎胞苷反应相关的染色质可及性分析
iScience. 2025 Aug 6;28(9):113297. doi: 10.1016/j.isci.2025.113297. eCollection 2025 Sep 19.
4
Comparative Analysis of IPSS, IPSS-R, and WPSS for Predicting Survival and Leukemic Transformation in Myelodysplastic Neoplasms: A Real-World Single-Center Experience.国际前列腺症状评分（IPSS）、修订版国际前列腺症状评分（IPSS-R）和世界卫生组织前列腺症状评分（WPSS）预测骨髓增生异常综合征生存和白血病转化的比较分析：一项单中心真实世界研究。
J Clin Med. 2025 Aug 14;14(16):5757. doi: 10.3390/jcm14165757.
5
Flow cytometric lyophilised reagent tube assay for peripheral blood neutrophil myeloperoxidase expression to rule out myelodysplastic neoplasms at a university hospital: a diagnostic accuracy study.大学医院采用流式细胞术冻干试剂管法检测外周血中性粒细胞髓过氧化物酶表达以排除骨髓增生异常肿瘤：一项诊断准确性研究
BMJ Open. 2025 Aug 22;15(8):e095640. doi: 10.1136/bmjopen-2024-095640.
6
, , and Mutations in Pediatric Leukemias.小儿白血病中的 、 和 突变
Cancers (Basel). 2025 Jul 23;17(15):2443. doi: 10.3390/cancers17152443.
7
Neutropenia (even mild) and anemia are poor prognostic factors in myelodysplastic syndromes.中性粒细胞减少症（即使是轻度）和贫血在骨髓增生异常综合征中是预后不良的因素。
Front Med (Lausanne). 2025 Jul 11;12:1558585. doi: 10.3389/fmed.2025.1558585. eCollection 2025.
8
Retreatment with PARPi following stem cell transplant in a patient with recurrent ovarian cancer and myelodysplastic syndrome.一名复发性卵巢癌合并骨髓增生异常综合征患者在干细胞移植后接受PARPi再治疗。
Gynecol Oncol Rep. 2025 Jul 14;60:101806. doi: 10.1016/j.gore.2025.101806. eCollection 2025 Aug.
9
AsS Mediates the ROS/P38 MAPK Signaling Pathway to Induce Apoptosis and S-Phase Arrest in Myelodysplastic Syndrome Cells.AsS介导ROS/P38 MAPK信号通路诱导骨髓增生异常综合征细胞凋亡和S期阻滞。
Curr Issues Mol Biol. 2025 Apr 7;47(4):253. doi: 10.3390/cimb47040253.
10
5-Azacytidine and decitabine induce C > G transversions in both murine and human cells.5-氮杂胞苷和地西他滨在小鼠和人类细胞中均诱导C→G颠换。
Leukemia. 2025 Jul 18. doi: 10.1038/s41375-025-02670-y.
Zotero 插件